Colorectal cancer (CRC) continues to be one of the leading cancer types worldwide. When metastasized the disease is generally incurable and only treated with palliative intent. Metastatic CRC (mCRC) is primarily treated with 5-fluorouracil and leucovorin administrated together with either the topoisomerase inhibitor irinotecan (FOLFIRI) or with the alkylating cytostatic oxaliplatin (XELOX/FOLFOX). Although these treatment regimens have significantly improved both disease-free and overall survival, drug resistance is still a major problem, and consequently, only half of the treated mCRC patients obtain an objective response to the selected first-line treatment.
Click here to view the full article in Epigenomics.